GT 02287
Alternative Names: GT-02287Latest Information Update: 03 Jul 2025
At a glance
- Originator Gain Therapeutics
- Class Antidementias; Antineoplastics; Antiparkinsonians; Neuroprotectants; Pharmacological chaperones; Small molecules
- Mechanism of Action Alpha 1-antitrypsin modulators; Galactosidase modulators; Galactosylceramidase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
- Preclinical Alpha 1-antitrypsin deficiency; Gaucher's disease; Globoid cell leukodystrophy; GM1 gangliosidosis; Solid tumours
- Research Dementia
Most Recent Events
- 30 Jun 2025 Adverse events data from a phase Ib trial in Parkinson's disease released by Gain Therapeutics
- 30 Jun 2025 Gain Therapeutics plans a phase II trial for Parkinson's disease in early 2026
- 11 Apr 2025 Interim pharmacodynamics data from a preclinical studies in Parkinson’s disease released by Gain Therapeutics